سعر سيسبلاتين 0.5 مجم/مل (50 مجم) فيال 2023

Cisplatin 0.5 mg/ml (50 mg) vial (Sandoz > B.P Pharma, Egypt). 50 mg cisplatin at 0.5 mg/ml. Pack: 1 vial (50 mg).

• US cisplatin: metastatic testicular tumours, metastatic ovarian tumours, and advanced bladder cancer (in combination regimens as labelled).Population: Adults (oncology)DailyMed (U.S. NLM)

• History of hypersensitivity to cisplatin or other platinum compounds; pre-existing severe renal impairment, myelosuppression or hearing impairment as labelled; pregnancy (unless life-threatening malignancy and no alternative).International label, same formulation · DailyMed (U.S. NLM)

• BOXED WARNINGS (US): nephrotoxicity, peripheral neuropathy, myelosuppression, severe nausea/vomiting, ototoxicity. Hydrate before/after infusion; monitor renal function, CBC, audiometry.International label, same formulation · DailyMed (U.S. NLM)
• Avoid aluminium-containing IV sets (reaction with platinum). Cumulative dose-related risks; secondary malignancies reported with platinum agents.International label, same formulation · DailyMed (U.S. NLM)

• Aminoglycosides / loop diureticsMajorAdditive nephrotoxicity and ototoxicity.DailyMed (U.S. NLM)
• PhenytoinModerateCisplatin may reduce phenytoin serum levels.DailyMed (U.S. NLM)

• US labels: can cause fetal harm; contraindicated in pregnancy unless benefit outweighs risk. Embryotoxic/teratogenic in animals.General active-ingredient information · DailyMed (U.S. NLM)
• Excreted in human milk; breastfeeding contraindicated during treatment.General active-ingredient information · DailyMed (U.S. NLM)

• Cisplatin: Forms intra-strand DNA cross-links (primarily guanine N7), inhibiting DNA replication and transcription, leading to apoptosis of susceptible tumour cells.